Supplementary Figure 1. Study design: The current analysis included patients from the randomised withdrawal-retreatment period (green) of COAST-Y.

Supplemental material placed on this supplemental material which has been supplied by the author(s).

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information herein or any errors or omissions. Supplemental material is supplied as is without any warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. The views and opinions expressed do not necessarily reflect those of BMJ or the supplement authors/issuers. Readers are encouraged to check the most up-to-date information provided by the issuing organization, and to verify any information before taking any actions or making any decisions. Any views or opinions expressed in this material are those of the author(s) and do not reflect the views of BMJ or any of its employees. BMJ shall not be liable for any losses, injuries, or damages from the display or use of this material. Supplementary material is not subject to the terms and conditions of the main publication. The views and opinions expressed in this material are those of the author(s) and do not reflect the views of BMJ or any of its employees. BMJ shall not be liable for any losses, injuries, or damages from the display or use of this material. Supplementary material is not subject to the terms and conditions of the main publication.

*Eligible patients continued to receive the same treatment (either 80 mg IXE Q2W or Q4W) as on their originating study. Patients completing COAST-X who were receiving blinded placebo were assigned to 80 mg IXE Q4W. Patients were eligible for entering the randomised withdrawal-retreatment period at week 24 if they achieved an ASDAS<1.3 at least once at week 16 or week 20, and <2.1 at both visits an ASDAS of <1.3 at least once during study visits. Patients who were eligible to enter the randomised withdrawal-retreatment period at week 24 were randomly assigned in a 2:1 ratio to continue IXE as per lead-in period or to withdraw to placebo, respectively, resulting in an overall 1:1:1 randomisation ratio. Patients who experienced a flare (ASDAS ≥2.1 at 2 consecutive visits or ASDAS >3.5 at any visit) were retreated at the next visit with the same IXE dosing regimen received during the lead-in period but in an OL fashion, except for patients originally from COAST-X, who received blinded retreatment until the COAST-X week-92 database lock. Flare: ASDAS ≥2.1 at 2 consecutive visits or ASDAS >3.5 at any visit. Recapture: Achieve ASDAS <2.1 (LDA) or ASDAS <1.3 (ID) following a flare. Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity; N, number of patients; OL, open-label; Q2W, every 2 weeks; Q4W, every 4 weeks.